SEELQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SEELQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Seelos Therapeutics's Trailing 12-Month Free Cash Flow is $-13.27 Mil, and Market Cap is $0.17 Mil. Therefore, Seelos Therapeutics's FCF Yield % for today is -7,762.57%.
The historical rank and industry rank for Seelos Therapeutics's FCF Yield % or its related term are showing as below:
During the past 13 years, the highest FCF Yield % of Seelos Therapeutics was -21.87%. The lowest was -80081355.93%. And the median was -2716.17%.
Seelos Therapeutics's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.
The historical data trend for Seelos Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seelos Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial | -53.29 | -24.27 | -28.50 | -84.65 | -175.64 |
Seelos Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
FCF Yield % | Get a 7-Day Free Trial | -15.91 | -78.35 | -56.15 | -205.93 | -196.04 |
For the Biotechnology subindustry, Seelos Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Seelos Therapeutics's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Seelos Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -23.912 | / | 13.6144384 | |
= | -175.64% |
Seelos Therapeutics's annualized FCF Yield % for the quarter that ended in Jun. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -0.972 | * | 4 | / | 1.98328176 | |
= | -196.04% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seelos Therapeutics FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Seelos Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Raj Mehra | director, officer: See Remarks | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Michael Joseph Golembiewski | officer: Chief Financial Officer | 7 TURTLE CT, FLEMINGTON NJ 08822 |
Daniel J. O'connor | director | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Margaret Dalesandro | director | ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534 |
Judith Dunn | director | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Brian Lian | director | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Robin L Smith | director | C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747 |
Neil Morton | officer: SVP, Chief Business Officer | C/O APRICUS BIOSCIENCES, INC., 11975 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Richard W Pascoe | director, officer: CEO & Secretary | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Armistice Capital Master Fund Ltd. | 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Alexander J Denner | 10 percent owner | C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Sarissa Capital Management Lp | 10 percent owner | 660 STEAMBOAT ROAD, GREENWICH CT 06830 |
Sarissa Capital Domestic Fund Lp | 10 percent owner | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
From GuruFocus
By PRNewswire PRNewswire • 03-29-2023
By PRNewswire • 11-24-2023
By PRNewswire • 12-22-2023
By PRNewswire PRNewswire • 02-13-2023
By PRNewswire • 12-01-2023
By GuruFocus Research • 12-02-2023
By PRNewswire PRNewswire • 05-05-2023
By PRNewswire • 09-21-2023
By PRNewswire • 03-19-2024
By PRNewswire • 11-29-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.